BRPI0606278B8 - aminas de 1,3-diidro-benzimidazol-2-ilideno como inibidores de replicação de vírus sincicial respiratório, seu processo de preparação e composição farmacêutica - Google Patents
aminas de 1,3-diidro-benzimidazol-2-ilideno como inibidores de replicação de vírus sincicial respiratório, seu processo de preparação e composição farmacêuticaInfo
- Publication number
- BRPI0606278B8 BRPI0606278B8 BRPI0606278A BRPI0606278A BRPI0606278B8 BR PI0606278 B8 BRPI0606278 B8 BR PI0606278B8 BR PI0606278 A BRPI0606278 A BR PI0606278A BR PI0606278 A BRPI0606278 A BR PI0606278A BR PI0606278 B8 BRPI0606278 B8 BR PI0606278B8
- Authority
- BR
- Brazil
- Prior art keywords
- hydrogen
- alkyl
- benzimidazol
- dihydro
- substituted
- Prior art date
Links
- -1 1,3-dihydro-benzimidazol-2-ylidene amines Chemical class 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 241000725643 Respiratory syncytial virus Species 0.000 title abstract 2
- 230000029812 viral genome replication Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000000160 oxazolidinyl group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001984 thiazolidinyl group Chemical group 0.000 abstract 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05102127 | 2005-03-17 | ||
| EP05102127.7 | 2005-03-17 | ||
| PCT/EP2006/060852 WO2006097534A1 (en) | 2005-03-17 | 2006-03-17 | 1,3-dihydro-benzimidazol-2-ylidene amines as inhibitors of respiratory syncytial virus replication |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0606278A2 BRPI0606278A2 (pt) | 2009-06-09 |
| BRPI0606278B1 BRPI0606278B1 (pt) | 2020-09-08 |
| BRPI0606278B8 true BRPI0606278B8 (pt) | 2021-05-25 |
Family
ID=34939009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0606278A BRPI0606278B8 (pt) | 2005-03-17 | 2006-03-17 | aminas de 1,3-diidro-benzimidazol-2-ilideno como inibidores de replicação de vírus sincicial respiratório, seu processo de preparação e composição farmacêutica |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7956196B2 (pt) |
| EP (1) | EP1951704B1 (pt) |
| JP (1) | JP5289934B2 (pt) |
| CN (1) | CN101142208B (pt) |
| AU (1) | AU2006224533B9 (pt) |
| BR (1) | BRPI0606278B8 (pt) |
| CA (1) | CA2600507C (pt) |
| ES (1) | ES2574670T3 (pt) |
| MX (1) | MX2007011292A (pt) |
| RU (1) | RU2410382C2 (pt) |
| WO (1) | WO2006097534A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070232673A1 (en) * | 2006-01-19 | 2007-10-04 | Roth Gregory P | 2-Imino-benzimidazoles |
| AU2009326259A1 (en) * | 2008-12-08 | 2011-07-28 | Boehringer Ingelheim International Gmbh | Compounds for treating cancer |
| EP3512840B1 (en) * | 2016-09-14 | 2024-03-06 | Yufeng Jane Tseng | Novel substituted benzimidazole derivatives as d-amino acid oxidase (daao) inhibitors |
| EP3594206A1 (en) | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-quinoline derivatives for treating a rna virus infection |
| EP3594205A1 (en) | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-aryl derivatives for treating a rna virus infection |
| HUE066072T2 (hu) * | 2019-07-19 | 2024-07-28 | Abivax | Aril-N-aril-származékok RNS vírus fertõzés kezelésére |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE31812B1 (en) * | 1967-02-03 | 1973-01-10 | Merck & Co Inc | Benzimidazole derivatives |
| JPS4842875B1 (pt) * | 1969-01-29 | 1973-12-14 | ||
| US4179505A (en) * | 1977-03-30 | 1979-12-18 | Janssen Pharmaceutica N.V. | 5-[4-(Diarylmethyl)-1-piperazinylalkyl]benzimidazole derivatives |
| EA005027B1 (ru) | 1999-06-28 | 2004-10-28 | Янссен Фармацевтика Н.В. | Ингибиторы репликации респираторно-синцитиального вируса |
| EE04592B1 (et) * | 1999-06-28 | 2006-02-15 | Janssen Pharmaceutica N.V. | Respiratoorse süntsütiaalviiruse replikatsiooni inhibiitorid, nende valmistamismeetod, kasutamine ja vaheühendid, farmatseutiline kompositsioon ja selle valmistamismeetod ning produkt |
| SG122814A1 (en) | 1999-06-28 | 2006-06-29 | Janssen Pharmaceutica Nv | Respiratory syncytial virus replication inhibitors |
-
2006
- 2006-03-17 ES ES06708798.1T patent/ES2574670T3/es not_active Expired - Lifetime
- 2006-03-17 CA CA2600507A patent/CA2600507C/en not_active Expired - Lifetime
- 2006-03-17 AU AU2006224533A patent/AU2006224533B9/en not_active Ceased
- 2006-03-17 EP EP06708798.1A patent/EP1951704B1/en not_active Expired - Lifetime
- 2006-03-17 WO PCT/EP2006/060852 patent/WO2006097534A1/en not_active Ceased
- 2006-03-17 BR BRPI0606278A patent/BRPI0606278B8/pt not_active IP Right Cessation
- 2006-03-17 RU RU2007138380/04A patent/RU2410382C2/ru active IP Right Revival
- 2006-03-17 MX MX2007011292A patent/MX2007011292A/es active IP Right Grant
- 2006-03-17 CN CN2006800085588A patent/CN101142208B/zh not_active Expired - Fee Related
- 2006-03-17 JP JP2008501332A patent/JP5289934B2/ja not_active Expired - Fee Related
- 2006-03-17 US US11/908,538 patent/US7956196B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101142208A (zh) | 2008-03-12 |
| EP1951704B1 (en) | 2016-03-16 |
| EP1951704A1 (en) | 2008-08-06 |
| RU2410382C2 (ru) | 2011-01-27 |
| BRPI0606278A2 (pt) | 2009-06-09 |
| BRPI0606278B1 (pt) | 2020-09-08 |
| CN101142208B (zh) | 2012-05-23 |
| CA2600507A1 (en) | 2006-09-21 |
| AU2006224533A1 (en) | 2006-09-21 |
| RU2007138380A (ru) | 2009-04-27 |
| AU2006224533B2 (en) | 2012-05-03 |
| CA2600507C (en) | 2013-10-22 |
| US7956196B2 (en) | 2011-06-07 |
| JP5289934B2 (ja) | 2013-09-11 |
| JP2008533103A (ja) | 2008-08-21 |
| MX2007011292A (es) | 2007-11-07 |
| AU2006224533B9 (en) | 2012-06-21 |
| ES2574670T3 (es) | 2016-06-21 |
| WO2006097534A1 (en) | 2006-09-21 |
| US20080146564A1 (en) | 2008-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0507065B8 (pt) | derivados de quinolina, composição que os compreende, seu processo de preparação e seu uso como inibidores micobacterianos | |
| BR112022017398A2 (pt) | Hidrato cristalino de um composto inibidor de jak | |
| BR0313160A (pt) | Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto | |
| BRPI0308495B8 (pt) | composto piridinoila útil para a ativação de receptores 5-ht1f, formulação farmacêutica, e, uso de um composto | |
| PL378064A1 (pl) | Pirymidyny i triazyny hamujące replikację wirusa HIV | |
| BR0113173A (pt) | Derivados de 4-fenil-piridina | |
| BRPI0417268A (pt) | benzimidazóis que contêm morfolinila, como inibidores da replicação de vìrus sinciciais respiratórios | |
| BRPI9909191B8 (pt) | derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende | |
| NO20083738L (no) | Sekundaere aminer som renininhibitorer | |
| CO6531445A2 (es) | Derivados bencimidazol-imidazol | |
| BRPI0407811A (pt) | composto derivados de pirazolopiridina, processo para a preparação dos mesmos, composição farmacêutica e respectivos uso | |
| BRPI0410660A (pt) | derivados de 2-amino-piridina como agonistas de adrenoreceptor ß2 | |
| BR0210538A (pt) | Derivados de 5-halotriptamina usados como ligantes dos receptores de serotonina 5-ht6 e/ou 5-ht7 | |
| BRPI0900983B8 (pt) | composto de diometina, processo para a síntese do mesmo, composição farmacêutica e seu uso | |
| NO20084186L (no) | Nye aminer | |
| BRPI0515081B8 (pt) | composto, processo para a preparação de um sal de guanidino trifluormetilaroil amida, processo para a preparação de um fenil amino pirido pirimidina, composições farmacêuticas e processos para preparar (3,5-bis trifluormetil)-n-[4-metil-3-(4-piridin-3-il-pirimidin-2-ilamino)-fenil]-benzamida | |
| BRPI0408767B8 (pt) | inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêutica | |
| BR112012014164A2 (pt) | inibidores da esfingosina quinase | |
| BR112012014884A2 (pt) | inibidores de esfingosina quinase | |
| BR112014001083A8 (pt) | composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto | |
| BRPI0414436A (pt) | processo para a preparação de derivados de 2-oxo-1-pirrolidina e seus sais | |
| MX2019008331A (es) | Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos. | |
| MX2024012014A (es) | Formas de sales de mesembrina | |
| BRPI0606278B8 (pt) | aminas de 1,3-diidro-benzimidazol-2-ilideno como inibidores de replicação de vírus sincicial respiratório, seu processo de preparação e composição farmacêutica | |
| BR112022002597A2 (pt) | Sal e formas cristalinas de um inibidor de cinase similar ao receptor de activina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: TIBOTEC PHARMACEUTICALS (IE) |
|
| B25D | Requested change of name of applicant approved |
Owner name: JANSSEN R AND D IRELAND (IE) |
|
| B25A | Requested transfer of rights approved |
Owner name: JANSSEN SCIENCES IRELAND UC (IE) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/09/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/03/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2766 DE 09-01-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |